Sign up
Pharma Capital

Scancell-led team short-listed for award

The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding
woman at microscope
The scientists are aiming to identify the most effective treatments for patients with most strains of the disease

A team led by Scancell Holdings Plc’s (LON:SCLP) chief scientific officer that is pioneering a vaccine-led approach to tackling tumours has been shortlisted for  a £20mln award.

Professor Lindy Durrant is teaming up with researchers from Genentech, BioNtech and ISA Pharmaceuticals to develop Project Blueprint.

The scientists are aiming to identify the most effective treatments for patients with most strains of the disease.

However the focus, at least initially, will be on head, neck lung, and pancreatic cancers as well as, glioblastoma - all of which currently have a poor prognosis.

Modi-3 may play a role

As part of the programme, Durrant’s team will consider whether Scancell’s Modi-3 product has a role to play.

Project Blueprint has been shortlisted for the Cancer Research UK Grand Challenge, a prestigious award that brings with it £20mln of funding.

Last year four teams won financial backing from the charity.

READ: Scancell eyeing investigational new drug application for SCIB1 in first half

Durrant said: “This brings us one step closer to delivering our cancer vaccine blueprint. 

“We believe this approach will provide an effective, novel therapy and facilitate the development of a comprehensive strategy of combinatorial cancer treatment for patients with most types of cancer. 

“Our unique academic-biotech-clinical partnership, facilitating access to reagents and clinical trials, positions us for success in this space."

View full SCLP profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.